Abbott Laboratories Net Long-Term Debt 2010-2024 | ABT
Abbott Laboratories annual/quarterly net long-term debt history and growth rate from 2010 to 2024. Net long-term debt can be defined as the net amount of long term debt issued and repaid. This field is either calculated as the sum of the long term debt fields or used if a company does not report debt issued and repaid separately
- Abbott Laboratories net long-term debt for the quarter ending September 30, 2024 was $0.202B, a 113.97% decline year-over-year.
- Abbott Laboratories net long-term debt for the twelve months ending September 30, 2024 was $-2.091B, a 4.65% decline year-over-year.
- Abbott Laboratories annual net long-term debt for 2023 was $-2.496B, a 234.58% increase from 2022.
- Abbott Laboratories annual net long-term debt for 2022 was $-0.746B, a 1595.45% increase from 2021.
- Abbott Laboratories annual net long-term debt for 2021 was $-0.044B, a 15.38% decline from 2020.
| Abbott Laboratories Annual Net Long-Term Debt (Millions of US $) |
|
|---|---|
| 2023 | $-2,496 |
| 2022 | $-746 |
| 2021 | $-44 |
| 2020 | $-52 |
| 2019 | $-1,599 |
| 2018 | $-8,424 |
| 2017 | $-1,908 |
| 2016 | $14,922 |
| 2015 | $2,428 |
| 2014 | $-577 |
| 2013 | $-294 |
| 2012 | $3,629 |
| 2011 | $-2,012 |
| 2010 | $2,326 |
| 2009 | $517 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $196.757B | $40.109B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stryker (SYK) | United States | $136.750B | 30.82 |
| Boston Scientific (BSX) | United States | $131.731B | 37.87 |
| EssilorLuxottica (ESLOY) | France | $109.710B | 0.00 |
| Medtronic (MDT) | Ireland | $102.865B | 15.28 |
| Haleon (HLN) | United Kingdom | $42.732B | 27.76 |
| Lonza Group Ag (LZAGY) | Switzerland | $42.382B | 0.00 |
| GE HealthCare Technologies (GEHC) | United States | $35.810B | 18.57 |
| ResMed (RMD) | United States | $33.540B | 27.56 |
| Terumo (TRUMY) | Japan | $28.681B | 40.51 |
| Koninklijke Philips (PHG) | Netherlands | $23.480B | 17.97 |
| Zimmer Biomet Holdings (ZBH) | United States | $20.795B | 13.24 |
| Insulet (PODD) | United States | $18.017B | 71.75 |
| Baxter (BAX) | United States | $14.940B | 9.72 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $10.667B | 0.00 |
| BellRing Brands (BRBR) | United States | $9.606B | 38.65 |
| Bio-Rad Laboratories (BIO) | United States | $9.131B | 31.03 |
| Demant (WILYY) | Denmark | $8.251B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.174B | 14.35 |
| Haemonetics (HAE) | United States | $3.938B | 19.22 |
| ICU Medical (ICUI) | United States | $3.868B | 36.83 |
| Prestige Consumer Healthcare (PBH) | United States | $3.840B | 19.10 |
| Perrigo (PRGO) | Ireland | $3.547B | 10.44 |
| Envista Holdings (NVST) | United States | $3.289B | 24.50 |
| QuidelOrtho (QDEL) | United States | $3.029B | 19.50 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| GN Store Nord (GNNDY) | Denmark | $2.863B | 18.36 |
| Neogen (NEOG) | United States | $2.587B | 29.85 |
| LeMaitre Vascular (LMAT) | United States | $2.057B | 49.98 |
| Green Thumb Industries (GTBIF) | United States | $1.724B | 30.17 |
| AtriCure (ATRC) | United States | $1.482B | 0.00 |
| InMode (INMD) | Israel | $1.424B | 8.57 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.386B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.305B | 9.33 |
| BioLife Solutions (BLFS) | United States | $1.214B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $1.066B | 0.00 |
| Owens & Minor (OMI) | United States | $0.991B | 7.74 |
| CeriBell (CBLL) | United States | $0.926B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.840B | 14.81 |
| Evolus (EOLS) | United States | $0.704B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.680B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.594B | 26.20 |
| Omeros (OMER) | United States | $0.570B | 0.00 |
| Surmodics (SRDX) | United States | $0.567B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.502B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.463B | 0.00 |
| Quanterix (QTRX) | United States | $0.415B | 0.00 |
| Valneva SE (VALN) | France | $0.384B | 0.00 |
| ZimVie (ZIMV) | United States | $0.382B | 32.16 |
| Biote (BTMD) | United States | $0.328B | 7.18 |
| Viemed Healthcare (VMD) | United States | $0.317B | 30.11 |
| Canopy Growth (CGC) | Canada | $0.314B | 0.00 |
| Cerus (CERS) | United States | $0.292B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.289B | 0.00 |
| High Tide (HITI) | Canada | $0.269B | 110.67 |
| OraSure Technologies (OSUR) | United States | $0.264B | 17.70 |
| Zynex (ZYXI) | United States | $0.249B | 52.07 |
| Aurora Cannabis (ACB) | Canada | $0.247B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.209B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.208B | 14.37 |
| MacroGenics (MGNX) | United States | $0.207B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.205B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.188B | 2.64 |
| Brainsway (BWAY) | Israel | $0.180B | 95.80 |
| TriSalus Life Sciences (TLSI) | United States | $0.152B | 0.00 |
| Jin Medical (ZJYL) | China | $0.149B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.148B | 18.59 |
| Quipt Home Medical (QIPT) | United States | $0.125B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.097B | 0.00 |
| Fonar (FONR) | United States | $0.096B | 10.79 |
| Veru (VERU) | United States | $0.095B | 0.00 |
| InterCure (INCR) | Israel | $0.072B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.072B | 37.00 |
| Jushi Holdings (JUSHF) | United States | $0.065B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.060B | 0.00 |
| Apyx Medical (APYX) | United States | $0.059B | 0.00 |
| Exagen (XGN) | United States | $0.055B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.050B | 0.00 |
| Modular Medical (MODD) | United States | $0.049B | 0.00 |
| ImmuCell (ICCC) | United States | $0.047B | 0.00 |
| Safety Shot (SHOT) | United States | $0.045B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.027B | 0.00 |
| Flora Growth (FLGC) | United States | $0.016B | 0.00 |
| Nephros (NEPH) | United States | $0.015B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.013B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.013B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.009B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.007B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.005B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| Agape ATP (ATPC) | $0.005B | 0.00 | |
| Sharps Technology (STSS) | United States | $0.004B | 0.00 |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 12.84 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |